Sumitomo Mitsui Trust Group, Inc.

The most aggressive move is the 901.7% ramp in KLA, now a $954.6M, 0.55% position. That is a textbook upgrade from AI narrative chips to the “picks-and-shovels” of process control — a call that the bottleneck (and margin pool) is in tools, not just GPUs.

On the health‑care side they lifted Eli Lilly by 6.8% to $2.27B, 1.30% of the book, paying up for a franchise that already sits on a 748.4% gain vs cost. That reads as conviction that obesity and metabolic drugs are not a trade but a multi‑year earnings re‑rating.

They also leaned into high‑end procedures: Intuitive Surgical was boosted 16.6% to $679.8M, explicitly backing surgical robotics as the downstream beneficiary of GLP‑1‑driven longevity and richer care regimes. In software and platforms, they quietly added to Alphabet class A, Amazon, Meta, and Palo Alto Networks, reinforcing an existing bet that scaled data, ad, and security platforms capture the durable cash flows around AI.

Finally, the fund made a meaningful statement in macro hedging: SPDR Gold MiniShares and iShares Gold Trust Micro were increased 7.9% and 5.2% respectively, taking them to a combined ~$2.72B. That isn’t a tactical nibble; it is a structural hedge sized to matter.

The sell tape is loudest in semis. NVIDIA, still the single largest disclosed holding at 6.69% and $11.71B, was trimmed by 3.5%, freeing up an estimated $420.4M. AMD and Micron were cut by 7.2% and 5.2%, with roughly $220.8M and $184.5M taken off the table.

Those three names all sit on enormous unrealized gains — 2,477.4% for NVIDIA, 1,712.3% for Micron, 491.7% for AMD. Trimming here looks less like a view change on AI demand and more like position‑size risk management and a conscious move down the stack into equipment (KLA, Applied Materials) where future incremental returns may be more attractive.

Away from semis, they eased off Alphabet class C, Cisco, and Intel, as well as large banks like JPMorgan and money‑center peers. The magnitude of those sales is modest relative to the book, suggesting funding flows rather than a macro call against US financials.

Consumer defensives and staples — Walmart, Procter & Gamble, Coca‑Cola — were gently clipped as well. Collectively, the trimming pattern says: harvest from crowded winners and low‑vol steady names, and redeploy into higher‑growth franchises and explicit macro insurance.

Headline sector weights barely moved — technology slipped from 60.53% to 60.44%, consumer discretionary ticked from 10.60% to 10.62%, and health care edged from 7.03% to 7.23%. Yet the internal trade within those buckets is doing the real work.

Within tech, the center of gravity is shifting from CPU/GPU exposure toward the broader AI supply chain: semiconductor equipment (KLA, Applied Materials, Lam Research) and analog/mixed‑signal names (Analog Devices, Texas Instruments) quietly gain share as direct chip bets are trimmed. That is a refinement from “own AI” to “own the capacity build‑out and control points.”

Health‑care exposure increases slightly but with a clear growth tilt: Eli Lilly and Intuitive Surgical both see meaningful adds, while Johnson & Johnson, Merck, and UnitedHealth are broadly maintained or marginally reduced. They are effectively upgrading the sector from defensive cash flows to high‑duration innovation.

The other conspicuous rotation is in the unclassified bucket: gold funds and Berkshire Hathaway now total 5.11% vs 4.92% previously. Energy, finance, and real estate all slip a touch, indicating that traditional inflation and rate hedges are being partially swapped for explicit gold exposure and a Berkshire‑style conglomerate ballast.

Taken together, the quarter sketches a manager that still believes in AI and US mega‑cap dominance, but is no longer willing to express that view only through the most obvious tickers. They’re migrating into the capex backbone — inspection, lithography‑adjacent tools, analog, and security — where competitive moats are wide and pricing power can persist even if GPU economics compress.

The bigger positions in Eli Lilly and Intuitive Surgical say they want exposure to secular health‑care growth that is uncoupled from the economic cycle. Those are long‑duration cash‑flow bets that pair well with high‑multiple tech.

On the risk side, the gold build‑out and slight trims to banks, energy, and defensives look like preparation for a more volatile macro regime: stick with structural winners, but layer in protection against policy error, inflation surprises, or multiple compression. If the past three years of strong performance are any guide, they’ll likely keep using market enthusiasm in AI and mega‑caps as a source of capital to fund more idiosyncratic, infrastructure‑heavy exposures.

For outside observers, the message is clear: this is not a wholesale style change, but a sharpening. Expect continued high tech weight, more emphasis on the AI and health‑care value chain rather than just its icons, and a quietly increasing allocation to real‑asset hedges.